Changes in light transmittance are determined by continuous measurements and are designated the clot waveform (CW). This complete clotting process recorded in the CWA is categorized into three parts, e.g. the pre-coagulation phase, the coagulation phase and the post-coagulation phase. After the onset of coagulation, light transmittance is decreased in association with the formation of fibrin and is defined by a slope in the waveform. The advantages of utilizing CWA

are provided by the quantitative assessment of various parameters derived by mathematically processing the waveform data. Early reports suggested, however, that |min1| and |min2| are promising parameters for quantitative evaluation of clotting function [2]. Observations of CWA patterns during routine aPTT and PT assays can provide

supportive and novel data in a variety Enzalutamide chemical structure of coagulation disorders and during monitoring of anti-coagulant therapy such as heparin. Characteristic CW patterns are observed in specific coagulation abnormalities compared with normal reference plasma, and two components, the duration of pre-coagulation phase and the steepness of the slope of the coagulation phase, appear to be especially informative. A further advantage offered by the application of CWA is the possibility of assessing fibrin deficiency and fibrinolytic activity. Furthermore, modification to a “biphasic” pattern is a Autophagy Compound Library price useful tool for diagnosis of sepsis and disseminated intravascular coagulation (DIC) [3]. CWA could discriminate between different levels of fVIII:C in this critical category of severe HA defined as having <1.0 IU dl−1 fVIII:C by conventional assays [2]. Furthermore, the CWA parameter, |min2|, appeared to be more directly correlated with both the degree of abnormality of

the CW and the fVIII:C MCE公司 level [4]. Similarly, in experiments in 36 patients with severe HA, significant correlations between |min2| and fVIII:C were confirmed, and the parameters correlated well with those of thrombin generation [4,5]. It is evident that since the distinction between severe and non-severe haemophilia cannot be determined precisely by the level of fVIII or fIX activity alone, the influence of other plasma components should be considered. It may be especially important that CWA can clearly discriminate between severe and non-severe groups. Defective clotting function in haemophilia can be assessed using CWA, and this method may be applicable to monitor the haemostatic and prophylactic effects of regular infusions of fVIII concentrate during ITI therapy in patients with inhibitor. Our previous results suggested that fVIII infusions may be continued with clinical benefit in some haemophilia patients with high responding inhibitors in whom the haemostatic response may be monitored effectively using CWA [6].